Generic Axid Availability
AXID (nizatidine - solution; oral)
Has a generic version of Axid been approved?
A generic version of Axid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Axid and have been approved by the FDA:
Manufacturer: AMNEAL PHARMS
Approval date: November 18, 2009
Strength(s): 15MG/ML [AA]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Axid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Liquid pharmaceutical composition
Issued: August 16, 2005
Inventor(s): Bobotas; George & Fawzy; Abdel A.
Assignee(s): Reliant Pharmaceuticals, Inc.
This invention relates to new pharmaceutical compositions and methods for their preparation, and in particular it relates to taste-masked liquid compositions comprising a solution of a histamine H2-antagonist complexed with an alginate and also containing a humectant. The solution is buffered to a pH of between about 6 to 7. The inventive solution may be flavored and sweetened and preserved.Patent expiration dates:
- July 17, 2022✓
- July 17, 2022
- Axid Consumer Information (Drugs.com)
- Axid Consumer Information (Wolters Kluwer)
- Axid solution Consumer Information (Wolters Kluwer)
- Axid Consumer Information (Cerner Multum)
- Axid AHFS DI Monographs (ASHP)
- Nizatidine Consumer Information (Wolters Kluwer)
- Nizatidine solution Consumer Information (Wolters Kluwer)
- Nizatidine Consumer Information (Cerner Multum)
- Nizatidine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AA||Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.|